Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.-Reference-Cited by-同舟云学术

Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.

Published:2017-09-23 Issue:4 Volume:5 Page:20
ISSN:2076-3271
Container-title:Medical Sciences
language:en
Short-container-title:Medical Sciences

Author:

Blanchette Christopher,Noone Joshua,Stone Glenda,Zacherle Emily,Patel Ripsi,Howden Reuben,Mapel Douglas

Publisher

MDPI AG

Subject

General Economics, Econometrics and Finance

Link

http://www.mdpi.com/2076-3271/5/4/20/pdf

Reference34 articles.

1. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013

2. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance

3. Prevalence and Economic Burden of Bronchiectasis

4. Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective

5. Prolonged antibiotics for purulent bronchiectasis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis;Journal of Medical Economics;2024-04-27

2. The Economic Burden of Bronchiectasis;CHEST;2023-12

3. Therapeutic effect and anti-biofilm ability assessment of a novel phage, phiPA1-3, against carbapenem-resistant Pseudomonas aeruginosa;Virus Research;2023-10

4. A Novel Approach To Identify Inhibitors of Iron Acquisition Systems of Pseudomonas aeruginosa;Microbiology Spectrum;2022-10-26

5. Development of a core outcome set and outcome measurement set for physiotherapy trials in adults with Bronchiectasis (COS-PHyBE study): A protocol;PLOS ONE;2022-02-08